CD5-targeted CAR-NK therapy for relapsed T-cell blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new therapy using your own immune cells (NK cells) engineered to find and kill cancer cells that carry the CD5 protein. It is for people with T-cell acute lymphoblastic leukemia or certain T-cell lymphomas that have not responded to treatment or have returned.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed T-cell leukemia or lymphoma that is resistant to treatment or has come back.
- Your cancer cells must test positive for the CD5 protein (most or all of them).
- You must be well enough to carry out daily activities (ECOG 0-2) and have a life expectancy of at least 12 weeks.
- Your heart, kidneys, liver, and lungs must be functioning adequately.
- You cannot have had certain prior treatments (like other CAR-cell therapies) or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This trial tests a new type of immune therapy—called CD5-targeting CAR T-cells—for people with a hard-to-treat form of T-cell acute lymphoblastic leukemia. It aims to see if these specially designed cells can find and destroy leukemia cells with the CD5 marker.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are reprogrammed to find and destroy T-cell leukemia or lymphoma cells that have the CD5 protein. It may be an option if your cancer has come back or hasn't responded to other treatments.
This trial tests a new treatment using your own immune cells, engineered to find and attack cancer cells that have a protein called CD5. It is for people with a type of T-cell lymphoma that has come back or not responded to other treatments.
This trial tests a new treatment using specially engineered immune cells (NK cells) that target the CD5 protein found on certain T-cell blood cancers. The cells are given after a short course of chemotherapy to help them work better. It may be an option for people with aggressive T-cell cancers that have not responded to standard therapy.
This trial tests an immune cell treatment (CAR-NK cells) targeting a protein called CD70 found on cancer cells. It's for people with T cell lymphoma or acute myeloid leukemia that has come back or not responded to other treatments.
Hear when a new T-ALL/Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.